CCMI
DGX icon

Creative Capital Management Investments’s Quest Diagnostics DGX Stock Holding History

Creative Capital Management Investments’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09K Buy
+24
New +$4.71K ﹤0.01% 401

Other funds holding DGX

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BCAM
Boston Common Asset Management Boston, Massachusetts $1.69B AUM 28.29% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Creative Capital Management Investments's DGX Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Quest Diagnostics (DGX) in Q2 2026: 24 shares worth $5.09K. The stake represents ﹤0.01% of the portfolio and ranks #401 among its holdings.

287 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Creative Capital Management Investments held 24 shares of Quest Diagnostics worth $5.09K as of Q2 2026.
  • Quest Diagnostics was a new Creative Capital Management Investments position in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #401 holding.
  • 287 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.